Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 10/20 | 0.98 |
| ▸ | DRD2 known ✓ | P14416 | 9/20 | 0.98 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 4/20 | 0.73 |
| ▸ | DRD4 known ✓ | P21917 | 6/20 | 0.65 |
| ▸ | DRD1 known ✓ | P21728 | 4/20 | 0.65 |
| ▸ | DRD5 | P21918 | 4/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | PRCP | P42785 | 1/20 | 0.64 |
| ▸ | EBP | Q15125 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5678691 | 1.00 | DRD3 (0.98) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| Hydrochloric Acid SCHEMBL29634866 | 1.00 | DRD3 (0.98) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| SCHEMBL873078 | 0.99 | DRD3 (1.00) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| SCHEMBL873549 | 0.99 | DRD3 (1.00) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| SCHEMBL29369425 | 0.99 | DRD3 (1.00) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| SCHEMBL873812 | 0.99 | DRD3 (1.00) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| Bromide SCHEMBL7023734 | 0.98 | DRD3 (0.98) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| Bromide SCHEMBL5699015 | 0.98 | DRD3 (0.98) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| SCHEMBL6880380 | 0.91 | DRD3 (0.84) | DRD3DRD2SIGMAR1DRD4DRD1 | |
| SCHEMBL6881711 | 0.91 | DRD3 (0.84) | DRD3DRD2SIGMAR1DRD4DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1455751-A1 | ZERO-ORDER SUSTAINED RELEASED DOSAGE FORMS AND METHOD OF MAKING THE SAME | Pharmacia Corporation (US) | 2004-09-15 | — | — | EP | claimed |
| US-20030133982-A1 | Zero-order sustained release dosage forms and method of making same | PHARMACIA CORPORATION | 2003-07-17 | — | — | US | claimed |
| WO-2003053402-A1 | ZERO-ORDER SUSTAINED RELEASED DOSAGE FORMS AND METHOD OF MAKING THE SAME | PHARMACIA CORPORATION (US) | 2003-07-03 | — | — | WO | claimed |
| EP-1274430-A2 | COMPOUNDS FOR TREATING FIBROMYALGIA AND CHRONIC FATIGUE SYNDROME | PHARMACIA & UPJOHN COMPANY (US) | 2003-01-15 | — | — | EP | claimed |
| WO-2001081343-A2 | COMPOUNDS FOR TREATING FIBROMYALGIA AND CHRONIC FATIGUE SYNDROME | PHARMACIA & UPJOHN COMPANY (US) | 2001-11-01 | — | — | WO | claimed |
| EP-3294337-B1 | TREATMENT OF DEBILITATING FATIGUE BY COMBINED USE OF 3(S)-3-[3-(METHYLSULFONYL)PHENYL]-1- PROPYLPIPERIDINE AND AN ANTI-DEPRESSIVE AGENT | ARVID CARLSSON RES AB (SE) | 2024-12-18 | — | — | EP | disclosed |
| US-20210106570-A1 | Treatment of Debilitating Fatigue | ARVID CARLSSON RESEARCH AB (SE) | 2021-04-15 | — | — | US | disclosed |
| US-10702512-B2 | Treatment of debilitating fatigue | A. CARLSSON RESEARCH AB (SE) | 2020-07-07 | — | — | US | disclosed |
| US-20190070156-A2 | Treatment of Debilitating Fatigue | ARVID CARLSSON RESEARCH AB (SE) | 2019-03-07 | — | — | US | disclosed |
| US-20180169081-A1 | Treatment of Debilitating Fatigue | A CARLSSON RES AB (SE) | 2018-06-21 | — | — | US | disclosed |
| EP-3294337-A1 | TREATMENT OF DEBILITATING FATIGUE | A.Carlsson Research AB (SE) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016180879-A1 | TREATMENT OF DEBILITATING FATIGUE | A. CARLSSON RESEARCH AB (SE) | 2016-11-17 | — | — | WO | disclosed |
| EP-1613333-A1 | ORAL EXTENDED RELEASE COMPRESSED TABLETS OF MULTIPARTICULATES | Pharmacia Corporation (US) | 2006-01-11 | — | — | EP | disclosed |
| US-6962998-B2 | Processes for producing racemic piperidine derivative and for producing optically active piperidine derivative | TORAY INDUSTRIES, INC. (JP) | 2005-11-08 | — | — | US | disclosed |
| WO-2004087175-A1 | ORAL EXTENDED RELEASE COMPRESSED TABLETS OF MULTIPARTICULATES | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| EP-1455751-A1 | ZERO-ORDER SUSTAINED RELEASED DOSAGE FORMS AND METHOD OF MAKING THE SAME | Pharmacia Corporation (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030133982-A1 | Zero-order sustained release dosage forms and method of making same | PHARMACIA CORPORATION | 2003-07-17 | — | — | US | disclosed |
| US-20030130313-A1 | Processes for producing racemic piperidine derivative and for producing optically active piperidine derivative | TORAY FINE CHEMICALS CO., LTD. (JP) | 2003-07-10 | — | — | US | disclosed |
| WO-2003053402-A1 | ZERO-ORDER SUSTAINED RELEASED DOSAGE FORMS AND METHOD OF MAKING THE SAME | PHARMACIA CORPORATION (US) | 2003-07-03 | — | — | WO | disclosed |
| EP-1295873-A1 | PROCESSES FOR PRODUCING RACEMIC PIPERIDINE DERIVATIVE AND FOR PRODUCING OPTICALLY ACTIVE PIPERIDINE DERIVATIVE | TORAY INDUSTRIES, INC. (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169081-A1 | Treatment of Debilitating Fatigue | COMT, MYOF, NEFM | DRD3 169/4885DRD2 119/4885SIGMAR1 532/4885 |
| US-10702512-B2 | Treatment of debilitating fatigue | COMT, MYOF, NEFM | DRD3 169/4885DRD2 119/4885SIGMAR1 532/4885 |
| US-20190070156-A2 | Treatment of Debilitating Fatigue | COMT, MYOF, NEFM | DRD3 169/4885DRD2 119/4885SIGMAR1 532/4885 |
| US-20030130313-A1 | Processes for producing racemic piperidine derivative and for producing optically active piperidine derivative | AMPD2, AMPD1, ITPA | DRD3 40/4885DRD2 16/4885SIGMAR1 756/4885 |
| US-20210106570-A1 | Treatment of Debilitating Fatigue | COMT, MYOF, NEFM | DRD3 169/4885DRD2 119/4885SIGMAR1 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.